King's College London

Research portal

Texture analysis of (125)I-A5B7 anti-CEA antibody SPECT differentiates metastatic colorectal cancer model phenotypes and anti-vascular therapy response.

Research output: Contribution to journalArticlepeer-review

Vineeth Rajkumar, Vicky Joo-Lin Goh, Muhammad Musib Siddique, Mathew Robson, Geoff Boxer, R Barbara Pedley, Gary John Russell Cook

Original languageEnglish
Pages (from-to)1882-1887
JournalBJC: British Journal of Cancer
Early online date19 May 2015
Accepted/In press17 Apr 2015
E-pub ahead of print19 May 2015
Published9 Jun 2015


  • Texture analysis of 125I-A5B7_RAJKUMAR)2015_GOLD VoR (CC BY-NC-SA)

    bjc2015166a.pdf, 543 KB, application/pdf

    Uploaded date:26 Jun 2017

    Version:Final published version

    Licence:CC BY-NC-SA

    This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons AttributionNonCommercial-Share Alike 4.0 Unported License.

King's Authors


Background: We aimed to test the ability of texture analysis to differentiate the spatial heterogeneity of 125I-A5B7 anti-carcinoembryonic antigen antibody distribution by nano-single photon emission computed tomography (SPECT) in well-differentiated (SW1222) and poorly differentiated (LS174T) hepatic metastatic colorectal cancer models before and after combretastatin A1 di-phosphate anti-vascular therapy. Methods: Nano-SPECT imaging was performed following tail vein injection of 20 MBq 125I-A5B7 in control CD1 nude mice (LS174T, n=3 and SW1222, n=4), and CA1P-treated mice (LS174T, n=3; SW1222, n=4) with liver metastases. Grey-level co-occurrence matrix textural features (uniformity, homogeneity, entropy and contrast) were calculated in up to three liver metastases in 14 mice from control and treatment groups. Results: Before treatment, the LS174T metastases (n=7) were more heterogeneous than SW1222 metastases (n=12) (uniformity, P=0.028; homogeneity, P=0.01; contrast, P=0.045). Following CA1P, LS174T metastases (n=8) showed less heterogeneity than untreated LS174T controls (uniformity, P=0.021; entropy, P=0.006). Combretastatin A1 di-phosphate-treated SW1222 metastases (n=11) showed no difference in texture features compared with controls (all P>0.05). Conclusions: Supporting the potential for novel imaging biomarkers, texture analysis of 125I-A5B7 SPECT shows differences in spatial heterogeneity of antibody distribution between well-differentiated (SW1222) and poorly differentiated (LS174T) liver metastases before treatment. Following anti-vascular treatment, LS174T metastases, but not SW1222 metastases, were less heterogeneous.

Download statistics

No data available

View graph of relations

© 2020 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454